J.M. del Campo

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

Tanguy Y. Seiwert, Jérôme Fayette, Didier Cupissol et al. · Annals of Oncology · 2014 · 182 citations · Full text

Medicine, Oncology, Pharmacology +17

Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy

Enriqueta Felip, J.M. del Campo, Diego Rubio et al. · Cancer · 1995 · 119 citations · Full text

Medicine, Gynecology, Oncology +17

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck

J.M. del Campo, Ricardo Hitt, P. Sebastian et al. · British Journal of Cancer · 2011 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab‐based therapy

Aleix Prat, Marta Parera, Vicky Reyes et al. · Head & Neck · 2007 · 98 citations

Medicine, Oncology, Metastasis +15

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

Ezra E.W. Cohen, Lisa Licitra, Barbara Burtness et al. · Annals of Oncology · 2017 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +16